Data will be presented for one arm. Treatment arm: Participants with advanced NSCLC, to receive AST -VAC2 Treatment Arm type : Experimental Arm Description : Participants will receive up to a maximum of six vaccinations over six weeks. Each weekly AST -VAC2 vaccination will be administered as a split dose via two intradermal injections at a target dose defined as 1 x 107 viable cells. There is no dose escalation planned during the study; only one dose level will be explor ed. Intervention type: Biological/Vaccine Intervention Name(s): AST-VAC2 Other Intervention Name(s) : N/A Intervention Description : Allogeneic dendritic cell vaccine. 1 ClinicalTrials.gov Results Data Element Definitions for Interventional and Observational Studies found here SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 29 7.2 Participant Flow The participant flow section of the results upload will include the following details. The programmed table output for reason not completed may be re -categori sed to ClinicalT rials.gov categories and reviewed by C linical Study Manager for approval. Period Title Overall Study Arm/Group Title Experimental: AST -VAC2 Arm/Group Description Participants will receive up to a maximum of six vaccinations over six weeks. Each weekly AST -VAC2 vaccination will be administered as a split dose via two intradermal injections at a target dose defined as 1 x 107 viable cells. There is no dose escalation planned during the study; only one dose level will be explored. Number of Participants Started (participants enrolled into main trial) * Complete d (6 vaccinations) Not completed Reason not completed Adverse Event Death Lack of Efficacy Lost to Follow -up Physician Decision Pregnancy Protocol Violation Withdrawal by Subject Disease Progression SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 30 Sponsor ’s decision to terminate the trial Started (participants entered follow -up period) Complete d (2-year OS follow up) Not completed Reason not completed Lost to follow -up Withdrawal of consent Death Declined to attend follow -up visit SM.TEMP.013 version 5 CRUKD/17/003 RAP Version: 2.0 09Mar2023 FINAL 31 7.3 Baseline Characteristics The baseline characteristics section of the results upload will include the following details. The programmed table output for reason not completed may be re-categori sed to C linicalT rials.gov categories and reviewed by C linical Study Manager for approval.